| scholarly article | Q13442814 |
| P50 | author | Saïk Urien | Q41653760 |
| Larry J Schaaf | Q43376154 | ||
| Tanios Bekaii-Saab | Q43376169 | ||
| P2093 | author name string | Amita Patnaik | |
| Anthony W Tolcher | |||
| Kyriakos P Papadopoulos | |||
| Muralidhar Beeram | |||
| Aby Buchbinder | |||
| Sanaa Tahiri | |||
| François M Lokiec | |||
| Keyvan Rezaï | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4 | Q28611359 | ||
| The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables. | Q30696416 | ||
| Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study | Q33256265 | ||
| Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects | Q35161323 | ||
| Irinotecan (CPT-11) metabolism and disposition in cancer patients. | Q36899508 | ||
| Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer | Q36915163 | ||
| Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma | Q37369959 | ||
| Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes | Q37378223 | ||
| Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis | Q37718359 | ||
| Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor | Q39668506 | ||
| Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers | Q39997823 | ||
| Clinical pharmacokinetics of irinotecan | Q40880283 | ||
| Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model | Q44005493 | ||
| The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. | Q44186061 | ||
| Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes | Q45137094 | ||
| Modified Fibonacci search. | Q52010988 | ||
| Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats | Q71254274 | ||
| Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials | Q77554663 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1499-1506 | |
| P577 | publication date | 2013-03-30 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer | |
| P478 | volume | 71 |
| Q47700115 | Camptothecin-based nanodrug delivery systems |
| Q38777221 | Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling |
| Q38180311 | Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor |
| Q44735229 | In vitro cytotoxicity, pharmacokinetics and tissue distribution in rats of MXN-004, a novel conjugate of polyethylene glycol and SN38. |
| Q92354302 | Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy |
| Q33775276 | Optimization of liposomal topotecan for use in treating neuroblastoma |
| Q28544821 | Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs |
| Q37441604 | Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study |
| Q33416097 | Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors |
| Q26774482 | Polymer-Based Prodrugs: Improving Tumor Targeting and the Solubility of Small Molecule Drugs in Cancer Therapy |
| Q57178229 | Renal Cell Carcinoma: Molecular Aspects |
| Q37671842 | SN-38-cyclodextrin complexation and its influence on the solubility, stability, and in vitro anticancer activity against ovarian cancer |
| Q30101057 | Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics |
| Q38674277 | Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy |
| Q53082813 | Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. |
Search more.